Idarubicin

CHEMBL1117 Phase 4 अनुमोदित Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
497.5 g/mol
LogP
1.9
Phase
4

This anthracycline chemotherapy drug works by inserting into DNA strands and inhibiting topoisomerase II, interfering with cancer cell DNA replication and causing cell death. It is used primarily to treat acute myeloid leukemia (AML) and some other leukemias. Cardiac toxicity is a significant concern, and cumulative dose limits must be observed.

आणविक भार

497.5000 g/mol

LogP

1.90

TPSA

177.00 Ų

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

क्रिया का तंत्र

Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.

2D संरचना

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O

InChI

InChI=1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1

Molecular Formula

C26H27NO9

HBD / HBA

5 / 10

घूर्णनीय बंधन

3

भारी परमाणु

36

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

This anthracycline chemotherapy drug works by inserting into DNA strands and inhibiting topoisomerase II, interfering with cancer cell DNA replication and causing cell death. It is used primarily to treat acute myeloid leukemia (AML) and some other leukemias. Cardiac toxicity is a significant concern, and cumulative dose limits must be observed.

Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.

Yes, Idarubicin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1117. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 42890. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.